Trinity Biotech (TRIB) Income from Continuing Operations (2016 - 2024)
Historic Income from Continuing Operations for Trinity Biotech (TRIB) over the last 16 years, with Q4 2024 value amounting to -$16.2 million.
- Trinity Biotech's Income from Continuing Operations fell 19382.72% to -$16.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$31.1 million, marking a year-over-year increase of 1636.89%. This contributed to the annual value of -$31.2 million for FY2024, which is 1560.05% up from last year.
- Latest data reveals that Trinity Biotech reported Income from Continuing Operations of -$16.2 million as of Q4 2024, which was down 19382.72% from -$4.8 million recorded in Q3 2024.
- In the past 5 years, Trinity Biotech's Income from Continuing Operations ranged from a high of $10.7 million in Q3 2020 and a low of -$18.6 million during Q2 2023
- Its 5-year average for Income from Continuing Operations is -$4.2 million, with a median of -$5.2 million in 2023.
- Per our database at Business Quant, Trinity Biotech's Income from Continuing Operations soared by 43611.89% in 2020 and then crashed by 203149.91% in 2022.
- Quarter analysis of 5 years shows Trinity Biotech's Income from Continuing Operations stood at $9.6 million in 2020, then crashed by 136.75% to -$3.5 million in 2021, then plummeted by 207.43% to -$10.8 million in 2022, then soared by 49.0% to -$5.5 million in 2023, then tumbled by 193.83% to -$16.2 million in 2024.
- Its Income from Continuing Operations stands at -$16.2 million for Q4 2024, versus -$4.8 million for Q3 2024 and -$6.9 million for Q2 2024.